Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole

Medicina

Volumn 67, Issue 4, 2007, Pages 326-330

  Sivori, Martin ^a   Rodriguez, Gabriel E ^a   Pascansky, Daniel ^a   Saenz, Cesar ^a   Sica, Roberto E P ^a  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

Amyotrophic lateral sclerosis; Non invasive ventilation; Riluzole; Survival

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ARGENTINA; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROPROTECTIVE AGENTS; POSITIVE-PRESSURE RESPIRATION; RILUZOLE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34548497428     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Dubrovsky A, Sica REP. Esclerosis lateral amiotrófica. Definición y criterios diagnósticos. En Sica REP, Dubrovsky A, eds. Esclerosis lateral amiotrófica y enfermedades relacionadas. Buenos Aires: Científica Interamericana, 2001, p. 27-36.
2. Miller RG; Mitchell JD; Lyon M; Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002; (2): CD001447.
3. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales ML. Respiratory assistance with a noninvasive ventilator (BiPAP in MND/ALS) patients: survival rates in controlled trial. J Neurol Sci 1995; 129: 19-26.
4. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Int Med 1997; 127: 450-3.
5. Gay P, Westbrook P, Daube JR, Litchy WJ, Windebank AJ, Iverson R. Effects of alterations in pulmonary function and sleep variables on survival in patients with Amyotrophic Lateral Sclerosis. Mayo Clin Proc 1991; 66: 686-94.
6. Caroscio TJ, Mulvihill MN, Sterling R, Abrams B. Amyotrophic Lateral Sclerosis: its natural history. Neurol Clin 1987; 5: 1-8.
7. Bach J. Amyotrophic Lateral Sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995; 76: 828-32.
8. De Vito E, Suárez A. Compromiso respiratorio en la esclerosis lateral amiotrófica. En Sica REP, Dubrovsky A, eds. Esclerosis lateral amiotrófica y enfermedades relacionadas. Buenos Aires: Científica Interamericana, 2001, p 215-77.
9. Suárez AA, Pessolano FA, Monteiro SG, et al. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil. 2002; 81: 506-11.
10. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology Criteria for the diagnosis of Amyotrophic Lateral Sclerosis. J Neurol Sci 1994; 124S: 96-107.
11. Brooks B, Miller G, Swash M, Munsat T. for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic lateral Sclerosis. (A Consensus Conference held at Airlie House, Warrenton, Virginia, April 2-4, 1998). Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
12. American Thoracic Society. Standardization of Spirometry. 1994 Update. Am. J Respir Crit Care Med 1995; 152: 1107-1136.
13. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969; 99: 696-702.
14. Dubrosky A, Sica R, Aguilera N, et al. Consenso Argentino para el Diagnóstico y Tratamiento de la Esclerosis Lateral Amiotrófica. Rev Neurol Arg 2001; 26: 93-101.
15. Clinical indications for the noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation: a consensus report. Chest 1999; 116: 521-34.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statiscal Association 1958; 53: 437-81.
17. Bensimon G, LaComblez L, Meininger V, and the ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91.
18. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, and the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31.